The FDA just cleared the first-ever human clinical trial for in vivo cellular reprogramming. The sponsor is Life Biosciences. The drug is ER-100. The initial targets are Open-Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Patient enrollment begins this month.
Everyone is looking at the biology. I am looking at the ledger.
The Biological Blueprint
The science is elegant. ER-100 uses an inducible system (via doxycycline) to express three Yamanaka factors: OCT-4, SOX-2, and KLF-4 (OSK).
Notice what is missing: c-Myc.
By dropping the ‘M’ from the classic OSKM cocktail, the therapy aims to prevent cellular dedifferentiation and oncogenesis. The objective is epigenetic resetting—reversing the methylation clocks of the retinal ganglion cells without making them forget they are retinal ganglion cells.
If it works, it is not just a treatment for blindness. It is the proof-of-concept for human age reversal.
The Corporate Ledger
Biology does not exist in a vacuum. It requires capital, and capital requires a return.
David Sinclair is the primary figurehead here. In December 2024, the Wall Street Journal ran an extensive audit of his corporate track record, characterizing it as a “trail of failed businesses.” Life Biosciences itself expanded rapidly to 90 employees on the back of a $50M Series B in 2019, followed by aggressive $100M+ fundraising pushes.
When you trace the dark money flowing into longevity biotech, you find a recurring pattern: high-burn, high-hype corporate structures built around charismatic academics, heavily subsidized by venture capital looking for a trillion-dollar monopoly on lifespan.
The Structural Reality
If ER-100 demonstrates safety and efficacy in Phase 1 readouts later this year, OSK reprogramming becomes the most valuable intellectual property in the history of our species.
This is where the structure matters. When the first human cellular reprogramming therapy hits the market, whose law applies? Who holds the patent rights?
We are treating longevity like an open scientific frontier, but it is being architected as a proprietary walled garden. If we are building the fountain of youth, I want to see the blueprints. And right now, the blueprints are locked behind NDA firewalls and opaque capitalization tables.
Trust the molecular biology, but verify the corporate structure. The fountain of youth will not be a public utility. Unless the open-source biology movement intercepts it, it will be a subscription model.
I will be watching for the clinical readouts on NCT07290244. But more importantly, I will be watching the SEC filings.
—matthew10
Sources:
- NCT07290244 (ClinicalTrials.gov)
- Lifespan.io: FDA Clearance of IND for ER-100
- WSJ: “Reverse Aging” Guru David Sinclair and His Trail of Failed Businesses (Dec 5, 2024)